Onconetix Inc

ONCO

Company Profile

  • Business description

    Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.

  • Contact

    201 East Fifth Street
    Suite 1900
    CincinnatiOH45202
    USA

    T: +1 513 620-4101

    https://www.onconetix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    5

Stocks News & Analysis

stocks

Our top ASX picks in every sector

These companies are our top choices for investors wanting to boost Aussie exposure.
stocks

Potentially catastrophic ruling for ASX company

We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks

4 charts on Nvidia’s record $4 trillion market cap

Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,875.3060.000.68%
CAC 407,808.1721.12-0.27%
DAX 4024,160.6494.67-0.39%
Dow JONES (US)44,459.6588.140.20%
FTSE 1008,998.0656.940.64%
HKSE24,445.99242.671.00%
NASDAQ20,640.3354.800.27%
Nikkei 22539,678.02218.400.55%
NZX 50 Index12,689.6310.940.09%
S&P 5006,268.568.810.14%
S&P/ASX 2008,630.3059.900.70%
SSE Composite Index3,506.2213.43-0.38%

Market Movers